Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Hedge Funds Reveal Latest Moves; Which Ones Should You Follow?

Page 1 of 2

With the latest round of 13F filings gathering pace, hedge fund managers are busy preparing to deluge us with the contents of their portfolios, which powers our market-beating small-cap strategy. However, that hasn’t stopped some of them from making fresh moves on a handful of stocks in the meantime. These include a biotech stock, a car-parts manufacturer and a tech stock, as well as a provider of marine transportation services. Let’s take a look at the companies that have caught the attention of hedge funds and why.

Clint Carlson

Let’s first take a step back and analyze how tracking hedge funds can help an everyday investor. Through our research we discovered that a portfolio of the 15 most popular small-cap picks of hedge funds beat the S&P 500 Total Return Index by nearly a percentage point per month on average between 1999 and 2012. On the other hand the most popular large-cap picks of hedge funds underperformed the same index by seven basis points per month during the same period. This is likely a surprise to many investors, who think of small-caps as risky, unpredictable stocks and put more faith (and money) in large-cap stocks. In forward tests since August 2012 these top small-cap stocks beat the market by an impressive 53 percentage points, returning 102% (read the details here). Follow the smart money into only their best investment ideas all while avoiding their high fees.

Clint Carlson seems to have changed his mind about Ultratech, Inc. (NASDAQ:UTEK) and has started buying the stock again. According to a recent filing with the Securities and Exchange Commission, Carlson Capital has acquired a total of 33,028 shares at prices varying between $14.94 and $14.99 apiece, boosting its stake in the company to 3.28 million shares or 11.9% of the company’s common stock.

Clint Carlson
Clint Carlson
Carlson Capital

So far this year, Ultratech, Inc. (NASDAQ:UTEK) has shed 15% of its value and is currently trading at $15.79 per share. For the three months ending July 4, 2015, the company posted revenues of $45.9 million and earnings of $0.06 per share, up from a loss of $0.23 per share a year earlier. Hedge funds didn’t appear to be anticipating much improvement as the number of funds invested in the company fell to 11 by the end of the second quarter, from 13 at the end of March. However, they own 22% of the company’s common stock and their holdings were valued at $113 million at the end of June, up by 19% over the quarter. Phill Gross and Robert Atchinson are also bullish on Ultratech, Inc. (NASDAQ:UTEK), having boosted their stake by 10% during the second quarter. In its latest 13F filing, Adage Capital Management reported ownership of 703,726 shares of Ultratech.

Follow Ultratech Inc (NASDAQ:UTEK)
Trade (NASDAQ:UTEK) Now!

Joseph Edelman, the manager of Perceptive Advisors, just can’t get enough of Aldeyra Therapeutics Inc (NASDAQ:ALDX). In his latest transaction, Edelman bought exactly 50,000 shares at an average price of $6.46, taking his stake to 1.19 million shares which account for 12.3% of the company’s outstanding stock.

Joseph Edelman
Joseph Edelman
Perceptive Advisors

Although it’s not a well-known company, Aldeyra Therapeutics Inc (NASDAQ:ALDX) can be found in the equity portfolios of seven hedge funds in our database as of June 30, up from four funds at the end of the first quarter. During the second quarter the value of their combined holdings rose by 160% as well, to $17.7 million, which accounts for nearly a quarter of Aldeyra’s common stock. Shares are currently trading at $6.95 apiece, down by 9.1% year-to-date. Aldeyra Therapeutics Inc (NASDAQ:ALDX) has not yet generated any revenues, as its first drug, NS2, is currently undergoing Phase IIa trials. Its next financial report is due November 9 and analysts are projecting a loss of $0.30 per share, down from $o.36 per share for the third quarter of 2014.

Follow Aldeyra Therapeutics Inc. (NASDAQ:ALDX)
Trade (NASDAQ:ALDX) Now!

We’ll check out the latest hedge fund action on Scorpio Bulkers Inc (NYSE:SALT) and Dana Holding Corporation (NYSE:DAN) on the next page.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!